PharmaEssentia: ROPEG expands across MPNs as 9M 2026 revenue reaches NTD 19.7B
น้อยกว่า 1 นาทีในการอ่าน
ROPEG’s PV reach exceeds 50 countries, with ET approvals added across four markets in 2026. Revenue reached NTD 19.7B in 9M 2026, while PMF Phase III enrollment and a broader oncology and immunology pipeline support expansion.
Original document: PharmaEssentia Corp. [6446] Slides Release — Nov. 13 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr